BTC Health Limited: Secures Exclusive Distribution Agreement with Eurosets

BTC Health Limited's (ASX: BTC) subsidiary, BTC Cardio Pty Ltd, has secured exclusive sales and distribution rights for Eurosets' comprehensive line of Cardiopulmonary and Extracorporeal Life Support (ECLS) products in Australia and New Zealand. This collaboration encompasses a wide array of high-quality ECLS and cardiopulmonary bypass items, including Horizon, Remowell 2, and Trilly 2 oxygenators essential for cardiac surgical bypass procedures. Eurosets, established in 1991 as part of the GVN Care&Research Group, is renowned for its biomedical expertise and supplies critical systems like Ecmolife and Colibri for ECLS.

Within Australia, where 12,700 coronary artery bypass graft procedures, 12,000 heart valve repairs or replacements, and 129 heart transplants were conducted in 2020/21, there's a growing need for these life-saving technologies. The national database recorded 451 cases of extracorporeal membrane oxygenation (ECMO) patients, highlighting the demand for such interventions, albeit with a significant cost of $305,463 per complex ICU admission.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com